- Augurex to attend CCR East 2025 and present new research on 14-3-3eta auto-antibodies as a diagnostic marker for axial spondyloarthritis (axSpA).
- Augurex will be exhibiting at booth #66, showcasing how the 14-3-3eta test aids in the diagnosis and monitoring of rheumatoid arthritis (RA) and how 14-3-3eta auto-antibodies are advancing diagnostics in axSpA.
Vancouver, Canada – April 24, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced its participation in CCR East 2025, taking place May 1–4 in Destin, Florida. The conference will bring together top rheumatologists, researchers, and industry leaders to explore the latest advancements in rheumatic disease diagnostics, treatments, and patient care.
At this year’s event, Augurex will present new research evaluating the diagnostic performance of 14-3-3eta auto-antibodies in axial spondyloarthritis (axSpA). The study showcases the potential of 14-3-3eta in early detection and demonstrating its ability to track changes in auto-antibody levels over time.
The findings highlight that 14-3-3eta auto-antibodies are significantly elevated in axSpA patients compared to healthy individuals. Additionally, antibody levels fluctuate over a one-year period, independent of treatment type or HLA-B27 status, further underscoring its potential value as a modifiable biomarker for disease progression.
Details of Augurex’s poster presentation are as follows:
- Poster Title: Diagnostic Potential and Modifiability of 14-3-3η Auto-Antibodies in Axial Spondyloarthritis (axSpA)
- Presenting Author: Dr. Nima Mazinani, PhD
- Date and Time: Friday, May 2 at 2:55 PM
In addition to the poster presentation, Augurex will be exhibiting at booth #66. Attendees are encouraged to visit the booth to learn more about Augurex’s innovative biomarker-driven diagnostic solutions for rheumatoid arthritis (RA) and axSpA, and how these advancements are helping to facilitate earlier diagnosis and improved patient management.
To learn more about CCR East 2025 or to connect with the Augurex team during the conference, visit:
Congress of Clinical Rheumatology – East 2025
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat™ in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
[email protected]